Cannabidiolic acid prevents vomiting in Suncus murinus and nausea‐induced behaviour in rats by enhancing 5‐HT1A receptor activation
暂无分享,去创建一个
M. Cascio | D. Bolognini | C. Limebeer | E. Rock | R. Pertwee | D Bolognini | EM Rock | NL Cluny | MG Cascio | CL Limebeer | M Duncan | CG Stott | FA Javid | LA Parker | RG Pertwee | C. Limebeer | R. Pertwee | M. Duncan | F. Javid | M. Cascio | LA Parker | N. Cluny | NL Cluny | E M Rock | CG Stott | Linda A. Parker | Colin Stott
[1] R. Pertwee. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. , 2008, British journal of pharmacology.
[2] R. Stern,et al. The effects of serotonin (5-HT3) receptor antagonists on gastric tachyarrhythmia and the symptoms of motion sickness. , 2000, Aviation, space, and environmental medicine.
[3] W. Johnson,et al. Importance of the vestibular system in visually induced nausea and self-vection. , 1999, Journal of vestibular research : equilibrium & orientation.
[4] R. Pertwee,et al. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9‐tetrahydrocannabinol, cannabidiol and Δ9‐tetrahydrocannabivarin , 2008 .
[5] R. Mechoulam,et al. A comparative analysis of the potential of cannabinoids and ondansetron to suppress cisplatin-induced emesis in the Suncus murinus (house musk shrew) , 2004, Psychopharmacology.
[6] C. Wilpizeski,et al. Motion‐Induced Sickness Following Bilateral Ablation of Area Postrema in Squirrel Monkeys , 1986, The Laryngoscope.
[7] I. Howard,et al. Visually-induced sickness in normal and bilaterally labyrinthine-defective subjects. , 1991, Aviation, space, and environmental medicine.
[8] L. Parker. Taste avoidance and taste aversion: Evidence for two different processes , 2003, Learning & behavior.
[9] A GRAYBIEL,et al. XXIV Effects of Labyrinthectomy on Canal Sickness in Squirrel Monkey , 1962, The Annals of otology, rhinology, and laryngology.
[10] R. Pertwee,et al. Evidence that the plant cannabinoid Δ9‐tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist , 2005, British journal of pharmacology.
[11] J T Reason,et al. Motion Sickness Adaptation: A Neural Mismatch Model 1 , 1978, Journal of the Royal Society of Medicine.
[12] J. Foubert,et al. Nausea: the neglected symptom? , 2004, European journal of oncology nursing : the official journal of European Oncology Nursing Society.
[13] H. Grill,et al. The taste reactivity test. I. Mimetic responses to gustatory stimuli in neurologically normal rats , 1978, Brain Research.
[14] T. Bisogno,et al. Effects of cannabinoids and cannabinoid‐enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes , 2011, British journal of pharmacology.
[15] David J Potter,et al. Potency of Δ9–THC and Other Cannabinoids in Cannabis in England in 2005: Implications for Psychoactivity and Pharmacology * , 2008, Journal of forensic sciences.
[16] C. Limebeer,et al. Conditioned nausea in rats: assessment by conditioned disgust reactions, rather than conditioned taste avoidance. , 2008, Canadian journal of experimental psychology = Revue canadienne de psychologie experimentale.
[17] R. Mechoulam,et al. Effects of cannabinoids on lithium-induced conditioned rejection reactions in a rat model of nausea , 2003, Psychopharmacology.
[18] R. Naylor,et al. The effect of the 5-HT1A receptor agonist, 8-OH-DPAT, on motion-induced emesis in Suncus murinus , 2006, Pharmacology Biochemistry and Behavior.
[19] R. Naylor,et al. The effects of cannabidiolic acid and cannabidiol on contractility of the gastrointestinal tract of Suncus murinus , 2011, Archives of pharmacal research.
[20] R. Mechoulam,et al. Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus (house musk shrew) , 2003, Psychopharmacology.
[21] F. Guimarães,et al. Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats , 2008, Psychopharmacology.
[22] D. Piomelli,et al. The effect of cannabidiol and URB597 on conditioned gaping (a model of nausea) elicited by a lithium-paired context in the rat , 2008, Psychopharmacology.
[23] C. C. Horn,et al. Chemotherapy agent cisplatin induces 48-h Fos expression in the brain of a vomiting species, the house musk shrew (Suncus murinus). , 2009, American journal of physiology. Regulatory, integrative and comparative physiology.
[24] R. Pertwee. The diverse CB 1 and CB 2 receptor pharmacology of three plant cannabinoids : D 9-tetrahydrocannabinol , cannabidiol and D 9-tetrahydrocannabivarin , 2007 .
[25] K. Abe,et al. Cannabidiol Prevents Cerebral Infarction Via a Serotonergic 5-Hydroxytryptamine1A Receptor–Dependent Mechanism , 2005, Stroke.
[26] R. Pertwee,et al. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro , 2007, British journal of pharmacology.
[27] I. Yamamoto,et al. Cannabidiolic Acid as a Selective Cyclooxygenase-2 Inhibitory Component in Cannabis , 2008, Drug Metabolism and Disposition.
[28] C. Kilkenny,et al. Guidelines for reporting experiments involving animals: the ARRIVE guidelines , 2010, British journal of pharmacology.
[29] H. Grill,et al. Chronically decerebrate rats demonstrate satiation but not bait shyness. , 1978, Science.
[30] J. Martínez-Orgado,et al. Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? , 2013, British journal of clinical pharmacology.
[31] R S Kennedy,et al. Symptomatology under storm conditions in the North Atlantic in control subjects and in persons with bilateral labyrinthine defects. , 1968, Acta oto-laryngologica.
[32] M. Qazilbash,et al. Clinical Efficacy of Lorazepam in Prophylaxis of Anticipatory, Acute, and Delayed Nausea and Vomiting Induced by High Doses of Cisplatin: A Prospective Randomized Trial , 1995, American journal of clinical oncology.
[33] F. Roila,et al. Impact of Nausea and Vomiting on Quality of Life in Cancer Patients During Chemotherapy , 2003, Health and quality of life outcomes.
[34] J. Atkins,et al. Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5‐hydroxytryptamine‐3 antiemetics , 2003, Cancer.
[35] G R Barnes,et al. The effect on motion sickness and oculomotor function of GR 38032F, a 5-HT3-receptor antagonist with anti-emetic properties. , 1989, British journal of clinical pharmacology.
[36] C. Limebeer,et al. Interaction between non-psychotropic cannabinoids in marihuana: effect of cannabigerol (CBG) on the anti-nausea or anti-emetic effects of cannabidiol (CBD) in rats and shrews , 2011, Psychopharmacology.
[37] P. C. Karlsson,et al. Evaluation of the cyclooxygenase inhibiting effects of six major cannabinoids isolated from Cannabis sativa. , 2011, Biological & pharmaceutical bulletin.
[38] F. Piscitelli,et al. Non‐psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action , 2011, British journal of pharmacology.
[39] K. Money,et al. THE ROLE OF THE SEMICIRCULAR CANALS IN CAUSATION OF MOTION SICKNESS AND NYSTAGMUS IN THE DOG. , 1964, Canadian journal of physiology and pharmacology.
[40] C. Limebeer,et al. Cannabinoids in the Management of Nausea and Vomiting , 2008 .
[41] G. Nomikos,et al. WIN 55,212-2 decreases the reinforcing actions of cocaine through CB1 cannabinoid receptor stimulation , 2003, Behavioural Brain Research.
[42] K. Ossenkopp,et al. Rotation-induced conditioned rejection in the taste reactivity test. , 1999, Neuroreport.
[43] P. Fletcher,et al. Cannabidiol, a non‐psychotropic component of cannabis, attenuates vomiting and nausea‐like behaviour via indirect agonism of 5‐HT1A somatodendritic autoreceptors in the dorsal raphe nucleus , 2012, British journal of pharmacology.
[44] V. Vellani,et al. Plant-Derived Cannabinoids Modulate the Activity of Transient Receptor Potential Channels of Ankyrin Type-1 and Melastatin Type-8 , 2008, Journal of Pharmacology and Experimental Therapeutics.
[45] Y. Cheng,et al. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.
[46] C. Limebeer,et al. Inverse agonism of cannabinoid CB1 receptors potentiates LiCl‐induced nausea in the conditioned gaping model in rats , 2010, British journal of pharmacology.
[47] K. Ossenkopp,et al. Vestibular lesions selectively abolish body rotation-induced, but not lithium-induced, conditioned taste aversions (oral rejection responses) in rats. , 2003, Behavioral neuroscience.
[48] G. Hall,et al. Exposure to a lithium-paired context elicits gaping in rats: A model of anticipatory nausea , 2006, Physiology & Behavior.
[49] R. Pertwee,et al. 6"-Azidohex-2"-yne-cannabidiol: a potential neutral, competitive cannabinoid CB1 receptor antagonist. , 2004, European journal of pharmacology.
[50] A. Chaudhury,et al. Brain Fos expression during 48 h after cisplatin treatment: Neural pathways for acute and delayed visceral sickness , 2007, Autonomic Neuroscience.
[51] R. Kennedy,et al. Symptomatology under storm conditions in the North Atlantic in control subjects and in persons with bilateral labyrinthine defects. NSAM-928. , 1965, Research report. Naval School of Aviation Medicine.
[52] G. Morrow,et al. Anticipatory nausea and vomiting in the era of 5-HT3 antiemetics , 1998, Supportive Care in Cancer.
[53] C. Limebeer,et al. Effect of Δ9-tetrahydrocannabinol on sucrose palatability as measured by the taste reactivity test , 2005, Physiology & Behavior.
[54] R. Naylor,et al. The effects of cannabidiol and tetrahydrocannabinol on motion-induced emesis in Suncus murinus. , 2008, Basic & clinical pharmacology & toxicology.
[55] R. Mechoulam,et al. Hashish. IV. The isolation and structure of cannabinolic cannabidiolic and cannabigerolic acids. , 1965, Tetrahedron.
[56] J. Verweij,et al. Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. , 1997, British Journal of Cancer.
[57] C. Biojone,et al. Antidepressant‐like effects of cannabidiol in mice: possible involvement of 5‐HT1A receptors , 2010, British journal of pharmacology.
[58] K. Horgan,et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy‐induced nausea and vomiting , 2003, Cancer.
[59] R. Nesse,et al. Pretreatment Nausea in Cancer Chemotherapy: A Conditioned Response?* , 1980, Psychosomatic medicine.
[60] A. Pastor,et al. Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. , 2010, British journal of clinical pharmacology.
[61] I. Cuthill,et al. Animal Research: Reporting In Vivo Experiments: The ARRIVE Guidelines , 2010, British journal of pharmacology.
[62] K. Ossenkopp,et al. Exposure to a context previously associated with nausea elicits conditioned gaping in rats: A model of anticipatory nausea , 2008, Behavioural Brain Research.
[63] R. Pertwee,et al. Structural determinants of the partial agonist‐inverse agonist properties of 6′‐azidohex‐2′‐yne‐Δ8‐tetrahydrocannabinol at cannabinoid receptors , 1999, British journal of pharmacology.
[64] A. Irving,et al. Modulation of l-α-Lysophosphatidylinositol/GPR55 Mitogen-activated Protein Kinase (MAPK) Signaling by Cannabinoids* , 2011, The Journal of Biological Chemistry.
[65] J. Vredenburgh,et al. Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting* , 2007, Current medical research and opinion.
[66] R Shaker,et al. Gastrointestinal motor and myoelectric correlates of motion sickness. , 1999, The American journal of physiology.
[67] F. Guimarães,et al. The anxiolytic-like effects of cannabidiol injected into the bed nucleus of the stria terminalis are mediated by 5-HT1A receptors , 2011, Psychopharmacology.